Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference

Thursday, September 17, 2009 General News J E 4
JERUSALEM, September 3 Oramed PharmaceuticalsInc. (OTC BB: ORMP.OB) (, a developer of alternativedrug delivery systems, announced today that Nadav Kidron, its Chief ExecutiveOfficer, is scheduled to present at the Rodman & Renshaw's 11th AnnualHealthcare Conference on Friday September 11, 2009 at 10:00 a.m. EDT. Theconference will be held at the New York Palace Hotel in New York City.

Nadav Kidron is scheduled to speak in the Fahnestock Salon on the fifthfloor of the hotel. He will discuss Oramed's strategic initiatives, updatesand product pipeline.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oraldelivery solutions for drugs and vaccines presently delivered via injection.Oramed is seeking to revolutionize the treatment of diabetes through itspatented flagship product, an orally ingestible insulin capsule currently inphase 2 clinical trials. Established in 2006, Oramed's technology is based onover 25 years of research by top research scientists at Jerusalem's HadassahMedical Center. The Company's corporate and R&D headquarters are based inJerusalem.

For more information, please visit

Forward-looking statements

Some of the statements contained in this press release areforward-looking statements which involve known and unknown risks,uncertainties and other factors which may cause the actual results,performance or achievements of the company, or industry results, to bematerially different from any future results, performance or achievementsexpressed or implied by such forward looking statements, including the risksand uncertainties related to the progress, timing, cost, and results ofclinical trials and product development programs; difficulties or delays inobtaining regulatory approval for our product candidates; competition fromother pharmaceutical or biotechnology companies; and the company's ability toobtain additional funding required to conduct its research, development andcommercialization activities. Please refer to the company's filings with theSecurities and Exchange Commission for a comprehensive list of risk factorsthat could cause actual results, performance or achievements of the companyto differ materially from those expressed or implied in such forward lookingstatements. The company undertakes no obligation to update or revise anyforward-looking statements.Company and Investor Relations Contacts: Oramed Pharmaceuticals Tara Horn USA: +1-646-240-4193 Office: +972-2-566-0001 Email:

SOURCE Oramed Pharmaceuticals Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Brain Injury Association of New York State to Host...
Helix Biopharma to Present at the Rodman & Renshaw...